Myfembree denied for missing prior authorization by Cigna?

Cigna's specific coverage criteria for myfembree are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Requires Prior Authorization for Myfembree — and How to Navigate the Process

Cigna requires prior authorization for Myfembree (relugolix, estradiol, and norethindrone acetate) as part of its utilization management program. This means coverage is available — but only after Cigna's medical reviewer confirms that the request meets the clinical criteria in Cigna's coverage policy. Understanding exactly what Cigna looks for, and building a submission that addresses every criterion before it is reviewed, dramatically improves approval rates and reduces the likelihood of a denial that requires a formal appeal.

## The Federal Appeal Framework

• Prior authorization submission: Your prescriber or their office typically submits the authorization request. Ask your prescriber to review Cigna's specific prior authorization criteria for Myfembree before submitting — ensuring all required clinical information is included from the outset.
• Peer-to-peer review: If the initial prior authorization is denied, your prescriber can request a peer-to-peer call with Cigna's reviewing medical director before a formal appeal is filed. This is often the fastest path to reversal.
• Internal appeal (Level 1): If the prior authorization is denied (or the peer-to-peer does not resolve it), file a written internal appeal within Cigna's deadline — typically 180 days from the denial. Cigna must issue a decision within 30 days for non-urgent pre-service appeals or 72 hours for expedited urgent requests.
• External review (ACA §2719): After a final internal denial, request independent external review — generally within 4 months of the adverse determination. The IRO applies generally accepted clinical standards to evaluate whether the denial was appropriate.
• ERISA §503: For employer-sponsored plans, Cigna must provide a detailed clinical rationale; a denial citing insufficient information must specify exactly what is missing.

## Documents to Gather

1. Cigna's prior authorization criteria: Obtain the specific clinical criteria Cigna requires for Myfembree authorization. Your prescriber's office can request this; it is also frequently available in Cigna's provider portal. 2. Diagnosis confirmation: Records documenting the diagnosis — endometriosis-associated pain or fibroid-related heavy menstrual bleeding — with sufficient clinical detail to establish severity. 3. Prior treatment history: A clear timeline of all relevant prior therapies, including agent names, dates of use, clinical response, and reason for discontinuation. Review the FDA-approved prescribing information for Myfembree to understand what prior-therapy documentation may be expected. 4. Prescriber medical-necessity letter: A letter from the treating physician that maps each of Cigna's authorization criteria to a specific patient chart finding or clinical fact. Vague letters are the most common reason for prior authorization denials. 5. Clinical severity documentation: Imaging, procedure records, symptom diaries, or other objective records demonstrating the impact of the condition on the patient.

## Criteria-Mapping Structure

Whether building the initial submission or an appeal, use a two-column table format:

• Column A: Each of Cigna's prior authorization criteria for Myfembree, quoted exactly.
• Column B: The specific chart entry, test result, date, or physician statement that satisfies each criterion.

Leave no criterion unaddressed. If a criterion does not apply or has been waived by prior treatment history, state that explicitly rather than leaving it blank. A complete, criteria-mapped submission is the single most reliable way to avoid a denial and obtain timely authorization.